Galapagos NV signs agreement to transfer Jyseleca business to Alfasigma
MECHELEN, BELGIUM: Galapagos NV and Alfasigma S.p.A. today announced that they have signed an agreement to transfer Galapagos’ Jyseleca® (filgotinib) business to Alfasigma, marking a...
e-therapeutics collaborates with Galapagos to discover new therapeutic strategies
OXFORD: e-therapeutics plc has entered a collaboration agreement with Galapagos NV to identify new therapeutic approaches to modulate a specific mechanism involved in idiopathic pulmonary...